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CGS: cutaneous granulocytic sarcoma
GS: granulocytic sarcoma
IHC: immunohistochemistry
KP: Koebner phenomenon
MDS: myelodysplastic syndrome
MPO: myeloperoxidase
PG: pyoderma gangrenosum
TGF-b1: transforming growth factor-beta 1
TGF-b1R: transforming growth factor-beta 1
receptorINTRODUCTION
Granulocytic sarcoma (GS) is also known as
myeloid sarcoma or chloroma because of its green
hue caused bymyeloperoxidase (MPO). This disease
involves the localization of myeloblasts or immature
myeloid cells to an extramedullary site. GS has
been described at numerous anatomic sites, but
cutaneous GS (CGS) is uncommon. Although CGS
is rare, it is clearly associated with myeloid disorders,
such as acute myeloid leukemia, myeloproliferative
neoplasms, and myelodysplastic syndromes (MDSs).
CGS may herald acute transformation, and it is
associated with a poor prognosis.1-3 However, the
mechanism underlying the specific migration of
myeloblasts to the skin remains uncertain. In 2008,
Kawakami et al4 presumed that transforming growth
factorebeta 1 (TGF-b1) released by hematopoietic
cells within the cutaneous extramedullary hemato-
poiesis could play a role in the onset of such skin
lesions.4
We report a case of a patient with MDS presenting
with 2 CGSs that developed consecutively at trauma-
tized skin sites, suggestive of the Koebner phenom-
enon (KP). Immunohistochemical (IHC) analysis
confirmed the expression of TGF-b1 on myeloblasts
and fibroblasts that had infiltrated the CGSs but also
showed the expression of its specific receptor
(TGF-b1R), suggesting a role for this cytokine in
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A 77-year-old man was admitted to our derma-
tology department with fevers and a 1-month
history of a hematoma on the left thigh, evolving
in an indurated necrotizing ulcerative plaque
(Fig 1). MDS was diagnosed 18 months prior
(refractory anemia with excess blasts I, normal
molecular cytogenetics, trisomy 8 in the tumoral
clone), which was treated with norethandrolone. A
complete blood count on admission showed
hemoglobin at 8.2 g/dL (normal ranges, 12.4-
14.9 g/dL), platelet level at 28 G/L (normal ranges,
150-400 G/L), a leukocytosis count at 5.8 103/mm3
(normal ranges, 4-10.103/mm3) but with circulating
blast cells, and a C-reactive protein level of
117 mg/L (normal, \6 mg/mL). Bone marrow
analysis confirmed qualitative abnormalities of theCorrespondence to: Christelle Le Gall-Ianotto, PhD, Laboratory of
Neurosciences of Brest, 22 Avenue Camille Desmoulins,
F-29200 Brest. E-mail: christelle_legall@hotmail.com.
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Fig 1. A, Lesions on the left thigh at the site of the hematoma. B, Biopsy of the infiltrated
necrotizing ulcerative plaque derived from the hematoma showed infiltration of hematopoietic
cells within the GS. (Hematoxylin-eosin stain; original magnification3100; inset,3400.) C, IHC
for MPO (1/300) showed the presence of numerous myeloblasts. (Original magnification,
3400).
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nucleated bone marrow cells.
A culture of the lesion found numerous
Staphylococcus aureus colonies, but no other organ-
ismswere identified. Histopathologic examination of
skin biopsies found a dense infiltration of blast cells
with round, not lobulated nuclei and scant
cytoplasm. The phenotype of myeloblasts was
characterized by various immunostains (CD451,
MPO1, MiB11, CD151, CD991, and CD681 and
CD34, CD33, CD4, and CD117) allowing the
diagnosis of CGS (Fig 1, B and C). A supplementary
IHC analysis found that TGF-ß1 and its specific
receptor, TGF-ß1R, were highly expressed in
immature hematopoietic cells and dermal fibroblasts
within the GS (Fig 2, A and B). The cutaneous lesion
had completely resolved 3 weeks after the resolution
of fevers, and the blood count normalized after
treatment with antibiotics (cloxacillin for 18 days,
1 g 3 times per day). Skin biopsy results confirmed
the complete regression of the GS.
Several days later, complete excision of a
squamous cell carcinoma located on the cheek
was performed. No myeloblasts were observed byhistologic examination of this lesion. However,
during the wound healing process (10 days after
surgery), a second GS was identified as a purple
plaque that had infiltrated and ulcerated around the
surgical wound (myeloblasts identified as CD451,
MPO1, MiB11, and CD34; Fig 3). Similar to the first
GS detected, expression of TGF-ß1 and TGF-ß1R
was observed on myeloblasts and dermal fibroblasts
within the GS (Fig 2, C and D). Complete and
spontaneous regression of the lesion was observed
3 weeks later.
Eighteen months later, the patient was still alive
and had received chemotherapy treatment, which
had been initiated after his GS episodes (3 rounds of
cytarabine/mitoxantrone) but did not cure his MDS.
Cutaneous surgery was avoided, and no skin lesions
were observed. No additional GS was diagnosed.
DISCUSSION
We describe 2 episodes of CGS that occurred
after trauma (hematoma and cutaneous surgery)
in the context of MDS. The differential diagnosis
included pyoderma gangrenosum (PG) and
aleukemic leukemia cutis. PG, the most common
Fig 2. IHC costaining of TGF-b1 and TGF-b1R (in red, white arrows) and MPO in brown in the
GS on the left thigh (A and B) and right cheek (C andD). A, TGF-b1 and B, TGF-b1R expression
in immature hematopoietic cells and dermal fibroblasts within the cutaneous GS on the left
thigh. C, TGF-b1 and D, TGF-b1R expression in immature hematopoietic cells and dermal
fibroblasts within the cutaneous GS on the right cheek. (Scale bar = 10 m.)
Fig 3. A, Lesions on the right cheek that developed after excision of squamous cell carcinoma.
B, Hematoxylin-eosin stain of the right cheek biopsy revealed numerous myeloblastic cells
within the GS (magnification,3100; inset,3400). C, IHC for MPO (1/300) showed the presence
of numerous myeloblasts (original magnification, 3400).
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excluded based on several clinical and histopatho-
logic characteristics.5 Clinically, the lesions did not
start as papules or pustules, were asymptomatic,
and were not associated with constitutional
symptoms. Histologically, the infiltrate of cells
was dense in the junction between dermis and
subcutis and composed of myeloblasts rather than
a massive dermal-epidermal neutrophilic infiltrate
with suppuration/abscess formation as in PG.
Aleukemic leukemia cutis was excluded based on
the absence of leukemic evolution 2 years after the
skin lesions developed and the negativity of CD34
and CD117 stains on infiltrated blast cells.
This type of GS resulting from skin trauma is
termed the KP or isomorphic response. The KP has
been associated classically with dermatologic
diseases (eg, psoriasis, lichen sclerosus), but it has
also been described in association with systemic
diseases.6 Some cases of GS occurring after a trauma
have been reported that did not result from the KP,
such as a GS that developed in a preexisting
hydroxyurea-induced leg ulcer in a polycythemia
vera patient and a GS masquerading as a
perianal abscess.7,8 Furthermore, a ‘‘pseudo-
Koebner’’ response was reported in an MDS patient,
but the absence of hematopoietic cells in the skin
biopsies did not allow for the verification of this case
as the true KP.9 In our case, the hematopoietic cells
detected in the skin biopsies during the wound
healing process were suggestive of the KP. Similar
to GS, the pathogenesis of the KP remains
obscure and has not been extensively studied.
However, involvement of inflammatory cells and
local production of various cytokines and adhesion
molecules have been suspected.6
The expression of chemokine receptors,
cytokines, and adhesion molecules by myeloblasts
and various skin cells could explain the localization
of GS to the skin. Byrd et al10 found that the
expression of CD56, an adhesion molecule, on
blast cells was a risk factor for extramedullary
tumors in one MDS case. In our case, IHC analysis
of skin samples found overexpression of the
TGF-b1/TGF-b1R pathway in immature hemato-
poietic cells and dermal fibroblasts during
cutaneous extramedullary hematopoiesis. Only
expression of TGF-b1 in association with MDS
was reported in the literature to date.4 TGF-b1 has
long been recognized as a key molecule acting both
during wound repair and tumor formation. Indeed,
it is a growth factor synthesized by skin cells
(eg, keratinocytes, fibroblasts) and actively
participates in the skin wound healing process by
increasing the inflammatory response, promotingboth myofibroblast activation and survival and
extracellular matrix remodeling.11,12 Thus, it was
not surprising to find TGF-b1 in our case, but its
expression on myeloblasts within the GS suggested
that this cytokine could be involved in the onset of
CGS. In MDS, the TGF-b1 pathway is constitutively
activated in MDS progenitors, suggesting that these
hematopoietic cells are more sensitive to this
cytokine.12 In any event, novel therapeutics
targeting the TGF-b1 pathway to regulate or inhibit
its constitutive activation of MDS progenitors have
been reported for the treatment of MDS.
Furthermore, TGF-b1 plays a central role in tumor
development by facilitating the extravasation of
metastasizing tumor cells.11 These data suggest that
TGF-b1, which is produced by cancer cells and skin
cells (eg, fibroblasts, immune cells), is able to create
a microenvironment that promotes the induction of
cancer cell migration and GS formation, thereby
explaining the KP.
The spontaneous regression of the 2 GSs in this
case may be explained by the negative feedback of
the amplification loop operated by TGF-b1 or
normalization of the TGF-b1 pathway during the
skin wound healing process. The exact role of
TGF-b1 and its specific receptor remains to be clearly
elucidated.
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